Evidence map›Paper›PMID 41702467›Full record

ArticleVascular pharmacology2026

Therapeutic perspective on cardiomyopathy and heart failure in older adults through the lens of chronic inflammation.

Hongyu Qiu, Inna P Gladysheva

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Vascular pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hongyu QiuCardiovascular Translational Research Center, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA; Clinical Translational Sciences and Bio5 Institution, University of Arizona, Tucson, AZ, USA. Electronic address: hqiu@arizona.edu.
Inna P GladyshevaCardiovascular Translational Research Center, Department of Internal Medicine, College of Medicine-Phoenix, University of Arizona, Phoenix, AZ, USA; Clinical Translational Sciences and Bio5 Institution, University of Arizona, Tucson, AZ, USA. Electronic address: innagladysheva@arizona.edu.

Funding

Intrinsic Stiffness of Aortic Vascular Smooth Muscle Cell in the Development of HypertensionR01HL115195 · NHLBI · UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL · PI QIU, HONGYU · 2013 to 2022
$5.1M
Role of VCP in coronary ischemic injuryR01HL142291 · NHLBI · LOMA LINDA UNIVERSITY · PI QIU, HONGYU, XIE, ZHONGLIN · 2018 to 2021
$2.6M
Factor XIIa is the long-sought activator of circulating renin in heart failure.R01HL171366 · NHLBI · UNIVERSITY OF ARIZONA · PI Inna P Gladysheva · 2024 to 2026
$1.5M
Novel mechanism mediating cardiac protection upon pressure overloadR01HL137962 · NHLBI · LOMA LINDA UNIVERSITY · PI QIU, HONGYU · 2018 to 2020
$1.2M
Novel mechanisms mediating cardiac protection upon pressure overloadR56HL137962 · NHLBI · LOMA LINDA UNIVERSITY · PI QIU, HONGYU · 2017 to 2017
$393k
NHLBI NIH HHS R01 HL115195NHLBI NIH HHS R01 HL137962NHLBI NIH HHS R01 HL142291NHLBI NIH HHS R01 HL171366NHLBI NIH HHS R56 HL137962
6 · The paper itself

Abstract

Cardiomyopathy is a disorder of the myocardium characterized by structural and functional abnormalities that result in impaired cardiac mechanical and/or electrical function. Aging induces a natural, gradual decline in cardiac structure and function (cardiac aging) that increases susceptibility to cardiomyopathy and exacerbates pre-existing cardiomyopathy. Despite ongoing research, the complex, multifactorial nature of this process substantially increases the risk of heart failure and remains a significant clinical and scientific challenge. With rising global life expectancy, effective pharmacological strategies are urgently needed. Here, we discuss chronic inflammation as a key driver of cardiomyopathy in older adults and explore perspectives on anti-inflammatory interventions that may slow disease progression and improve outcomes for the older population.

Indexed as

AgingAnti-Inflammatory AgentsCardiomyopathiesHeart FailureInflammationInflammation MediatorsAgedAge FactorsAnimalsChronic DiseaseDisease ProgressionHumansMyocardiumRisk FactorsSignal TransductionTreatment OutcomeAnti-Inflammatory AgentsInflammation MediatorsCardiac agingCardiomyopathyHeart failureInflammagingInflammationSenescence-associated secretory phenotype

Identifiers

PMID41702467
PMCPMC13201211

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.